Reclassification of series B shares in Moberg Pharma AB (publ)
STOCKHOLM, November 29[th], 2019. During November 2019, Moberg Pharma AB (publ) (“Moberg Pharma” or the “Company”) has, in accordance with the conversion clause in the Company’s articles of association, reclassified 660,843 series B shares into the same number of ordinary shares. The reclassification entails an increase in the number of ordinary shares and a decrease in the number of series B shares, but does not affect the total number of shares or votes in the Company.Before the reclassification, the total number of shares in Moberg Pharma amounted to 18,853,510, of which 18,192,667 were